Giancarlo Feliciello

Dedicated and skilled molecular biologist with over 10 years of professional lab experience, projects organization and management with very good knowledge of quality practices and regulatory frameworks. Very interested and keen on all aspects of liquid biopsy, especially biomarker discovery, and its application in the field of precision medicine as mean to target the right treatments at the right time for patients suffering cancer disease. Solution-oriented person with attitude to bring challenging projects to success.

Identification of circulating multiple myeloma cells (CMMC) through combined genome and proteome sequencing (G&P-seq)

• Development of a

Customizing and/or testing "low input DNA/RNA" workflows for public and private companies 

• Successful design, development and customization of protocols using single cells or low-input DNA/RNA (cfDNA, cfRNA exosome DNA) tailored to the desired applications and sample conditions required from the customers (e.g. Menarini-Silicon Biosystems, Telexos).

Bavarian Cancer Research Center (BZKF)-CNS malignancies 

• Successful establishment of pre-analytical standards for biomarkers studies exploring cerebrospinal fluid, and technologies for minimally invasive, longitudinal, molecular genetic characterization of small numbers of tumor cells and cfDNA.

Fraunhofer Cluster of Excellence Immune-Mediated Diseases: early diagnosis of subclinical arthritis   

• Development of a serological biomarker profile for the differentiation of psoriasis vulgaris and psoriatic arthritis, as well as for early diagnosis of subclinical arthritis using cell-free RNA signature (circular RNA and miRNA).

• Writing project proposals and participation to grant application
• Scientific and operational leadership, including experimental planning and matching timelines of project deliverables
• Budgeting for consumables and personnel costs at Fraunhofer ITEM
• Representing and reporting projects to consortium management
• Regular meetings with scientists and technical assistants to monitor project progress and troubleshooting

Ex vivo expansion of lung cancer-derived disseminated cancer cells from lymph nodes identifies cells associated with metastatic progression.

Treitschke S, Weidele K, Varadarajan AR, Feliciello G, Warfsmann J, Vorbeck S, Polzer B, Botteron C, Hoffmann M, Dechand V, Mederer T, Weber F, Werner-Klein M, Robold T, Hofmann HS, Werno C, Klein CA.  Int J Cancer. 2023 Aug 9.  

Disseminated cancer cells detected by immunocytology in lymph nodes of NSCLC patients are highly prognostic and undergo parallel molecular evolution.

Elsner F, Hoffmann M, Fahrioglu-Yamaci R, Czyz Z, Feliciello G, Mederer T, Polzer B, Treitschke S, Rümmele P, Weber F, Wiesinger H, Robold T, Sziklavari Z, Sienel W, Hofmann HS, Klein CA. J Pathol. 2022 Nov;258(3):250-263. 

Detection of Genomically Aberrant Cells within Circulating Tumor Microemboli (CTMs) Isolated from Early-Stage Breast Cancer Patients.

Silvestri M, Reduzzi C, Feliciello G, Vismara M, Schamberger T, Köstler C, Motta R, Calza S, Ferraris C, Vingiani A, Pruneri G, Daidone MG, Klein CA, Polzer B, Cappelletti V. Cancers (Basel). 2021 Mar 19;13(6):1409.

Interleukin-6 trans-signaling is a candidate mechanism to drive progression of human DCCs during clinical latency.

Werner-Klein M, Grujovic A, Irlbeck C, Obradović M, Hoffmann M, Koerkel-Qu H, Lu X, Treitschke S, Köstler C, Botteron C, Weidele K, Werno C, Polzer B, Kirsch S, Gužvić M, Warfsmann J, Honarnejad K, Czyz Z, Feliciello G, Blochberger I, Grunewald S, Schneider E, Haunschild G, Patwary N, Guetter S, Huber S, Rack B, Harbeck N, Buchholz S, Rümmele P, Heine N, Rose-John S, Klein CA. Nat Commun. 2020 Oct 5;11(1):4977.

Tumor Cell Invasion in Glioblastoma.

Vollmann-Zwerenz A, Leidgens V, Feliciello G, Klein CA, Hau P. Int J Mol Sci. 2020 Mar 12;21(6):1932.

 
Microfluidic enrichment, isolation and characterization of disseminated melanoma cells from lymph node samples.

Weidele K, Stojanović N, Feliciello G, Markiewicz A, Scheitler S, Alberter B, Renner P, Haferkamp S, Klein CA, Polzer B. Int J Cancer. 2019 Jul 1;145(1):232-241.